Ankur Jindal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ankur Jindal has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adam Whaley-Connell
Department of Medicine–Endocrinology and Metabolism (A.W.-C., G.J.), University of Missouri School of Medicine, Columbia
2 shared publications - James R. Sowers
University of Missouri School of Medicine
2 shared publications James R. Sowers
Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, Mo., USA
1 shared publication- Mariana Garcia-Touza
Diabetes and Cardiovascular Research Center, University of Missouri, Columbia, Missouri, USA
1 shared publication - Nidhi Jindal
Division of Nephrology and Hypertension, Department of Internal Medicine University of Missouri Columbia School of Medicine, Columbia, Missouri, USA
1 shared publication Stephen Brietzke
Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, Mo., USA
1 shared publication
Latest Publications
- 1 September 2016
- Published by SAGE Publications in Thyroid®
- Vol. 26 (9) , 1334-1335
Is Thyroglobulin Level by Liquid Chromatography Tandem-Mass Spectrometry Always Reliable for Follow-Up of DTC After Thyroidectomy: A Report on Two Patients
- 1 September 2016
- Published by SAGE Publications in Thyroid®
- Vol. 26 (9) , 1334-1335
Is Thyroglobulin Level by Liquid Chromatography Tandem-Mass Spectrometry Always Reliable for Follow-Up of DTC After Thyroidectomy: A Report on Two Patients
- 1 December 2013
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 42 (4) , 789-808
Diabetic Kidney Disease and the Cardiorenal Syndrome
- 1 December 2013
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 42 (4) , 789-808
Diabetic Kidney Disease and the Cardiorenal Syndrome
- 28 March 2013
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 7 (3) , 233-237
Type 2 Diabetes in Older People; The Importance of Blood Pressure Control
Diabetes and hypertension often coexist and their coexistence substantially promotes cardiovascular disease (CVD) and chronic kidney disease. Control of blood pressure to a level of 140/90 mmHg in people with diabetes can prevent or at least delay CVD and chronic kidney disease. In the past many society treatment guidelines have stressed tight blood pressure control (=<130/80) for people with diabetes. But recommendations for such tight blood pressure control have not been supported by recent large randomized control trials, especially in in elderly. Here we review the recent literature regarding the benefits of blood pressure control in elderly patients with diabetes. We further focus on evidence for specific levels of blood pressure treatment goals, in this population subset.
- 28 March 2013
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 7 (3) , 233-237
Type 2 Diabetes in Older People; The Importance of Blood Pressure Control
Diabetes and hypertension often coexist and their coexistence substantially promotes cardiovascular disease (CVD) and chronic kidney disease. Control of blood pressure to a level of 140/90 mmHg in people with diabetes can prevent or at least delay CVD and chronic kidney disease. In the past many society treatment guidelines have stressed tight blood pressure control (=<130/80) for people with diabetes. But recommendations for such tight blood pressure control have not been supported by recent large randomized control trials, especially in in elderly. Here we review the recent literature regarding the benefits of blood pressure control in elderly patients with diabetes. We further focus on evidence for specific levels of blood pressure treatment goals, in this population subset.
- 24 November 2012
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 2 (4) , 314-327
Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors
The prevalence of obesity has increased rapidly in the United States. Obesity affects about one third of the adult population and, even though it is attributed to excess calorie intake and inadequate physical activity, its etiopathogenesis is much more complex and is an area of active study. Lifestyle modifications (with a focus on increased activity and decreased calorie intake) have modest efficacy in the treatment of obesity. There is a dearth of safe and effective therapeutic modalities to treat obesity. In this review, we discuss the role of different treatment options in the management of obesity and its comorbidities, with a focus on recently approved drugs and the emerging role of bariatric surgery.
- 24 November 2012
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 2 (4) , 314-327
Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors
The prevalence of obesity has increased rapidly in the United States. Obesity affects about one third of the adult population and, even though it is attributed to excess calorie intake and inadequate physical activity, its etiopathogenesis is much more complex and is an area of active study. Lifestyle modifications (with a focus on increased activity and decreased calorie intake) have modest efficacy in the treatment of obesity. There is a dearth of safe and effective therapeutic modalities to treat obesity. In this review, we discuss the role of different treatment options in the management of obesity and its comorbidities, with a focus on recently approved drugs and the emerging role of bariatric surgery.